Yazar "Havrdova, Eva" için listeleme
-
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Lorscheider, Johannes; Jokubaitis, Vilija G.; Spelman, Tim; Izquierdo, Guillermo; Lugaresi, Alessandra; Havrdova, Eva; Granella, Franco (Lippincott Williams & Wilkins, 2017)Objective: To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS). Methods: Using MSBase, an international cohort study, we previously ... -
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
Brown, J. William L.; Coles, Alasdair; Horakova, Dana; Havrdova, Eva; Izquierdo, Guillermo; Prat, Alexandre; Pucci, Eugenio (Amer Medical Assoc, 2019)IMPORTANCE Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressiveMS. The association between ... -
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Kalincik, Tomas; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Havrdova, Eva; Trojano, Maria; Barnett, Michael (Sage Publications Ltd, 2018)Objective: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon , fingolimod or natalizumab. Methods: We identified all patients with relapse-onset multiple sclerosis, ... -
A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
Spelman, Timothy; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Lugaresi, Alessandra; Izquierdo, Guillermo; Butzkueven, Helmut (Lippincott Williams & Wilkins, 2018)… -
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
He, Anna; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Luis Sanchez-Menoyo, Jose (Amer Medical Assoc, 2015)IMPORTANCE After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is ... -
Defining reliable disability outcomes in multiple sclerosis
Kalincik, Tomas; Cutter, Gary; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Ramo, Cristina (Oxford Univ Press, 2015)Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. The disability outcomes used in most clinical trials rely on progression of Expanded Disability ... -
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis
Tao, Chunrong; Simpson, Steve; van der Mei, Ingrid; Blizzard, Leigh; Havrdova, Eva; Horakova, Dana; Barnett, Michael (Bmj Publishing Group, 2016)Background Age at onset (AAO) in multiple sclerosis (MS) is an important marker of disease severity and may have prognostic significance. Understanding what factors can influence AAO may shed light on the aetiology of this ...
